Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Average Recommendation of “Reduce” from Analysts

Posted by Stanley Muller on Aug 11th, 2026

Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Free Report) have been given an average recommendation of “Reduce” by the eight brokerages that are covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating and six have assigned a hold rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $22.00.

AMPH has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, July 8th. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Friday, May 8th. Wall Street Zen raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday. Wells Fargo & Company raised their price target on shares of Amphastar Pharmaceuticals from $19.00 to $20.00 and gave the stock an “equal weight” rating in a report on Friday. Finally, Zacks Research raised shares of Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 21st.

Check Out Our Latest Stock Report on AMPH

Amphastar Pharmaceuticals Stock Down 2.3%

Shares of NASDAQ:AMPH opened at $20.31 on Tuesday. Amphastar Pharmaceuticals has a 1 year low of $16.65 and a 1 year high of $31.26. The company has a debt-to-equity ratio of 0.79, a current ratio of 2.40 and a quick ratio of 1.71. The business’s 50-day moving average is $19.70 and its 200-day moving average is $21.32. The company has a market capitalization of $863.99 million, a price-to-earnings ratio of 12.02, a P/E/G ratio of 4.39 and a beta of 0.89.

Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.62 by $0.29. The business had revenue of $183.90 million during the quarter, compared to analysts’ expectations of $179.92 million. Amphastar Pharmaceuticals had a return on equity of 14.98% and a net margin of 10.76%. Equities research analysts predict that Amphastar Pharmaceuticals will post 2.25 earnings per share for the current year.

Institutional Trading of Amphastar Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quarry LP bought a new position in Amphastar Pharmaceuticals in the third quarter worth approximately $32,000. Farther Finance Advisors LLC increased its holdings in shares of Amphastar Pharmaceuticals by 46.3% during the fourth quarter. Farther Finance Advisors LLC now owns 1,381 shares of the company’s stock valued at $37,000 after acquiring an additional 437 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Amphastar Pharmaceuticals by 24.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,233 shares of the company’s stock worth $60,000 after purchasing an additional 435 shares during the period. TD Private Client Wealth LLC lifted its holdings in shares of Amphastar Pharmaceuticals by 410.1% in the 4th quarter. TD Private Client Wealth LLC now owns 2,418 shares of the company’s stock worth $65,000 after purchasing an additional 1,944 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Amphastar Pharmaceuticals by 263.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,583 shares of the company’s stock worth $82,000 after purchasing an additional 2,596 shares in the last quarter. 65.09% of the stock is owned by institutional investors.

Amphastar Pharmaceuticals Company Profile

(Get Free Report)

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.